Related Experiment Video

Updated: Dec 11, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.4K

Nuclear Receptors as Potential Therapeutic Targets for Myeloid Leukemia

Pan Pan1, Xiao Chen1

  • 1Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA.

Cells
|August 23, 2020
PubMed

Insights

Nuclear receptors (NRs) show therapeutic potential in myeloid leukemia. Targeting receptors like RAR, VDR, and PPAR can induce differentiation and apoptosis, offering new treatment strategies.

Area of Science:

  • Molecular Biology
  • Oncology
  • Pharmacology

Background:

  • Nuclear receptors (NRs) are well-studied in solid tumors, but their roles in leukemia are less understood.
  • Certain NRs are crucial for myeloid cell differentiation, presenting therapeutic opportunities for myeloid leukemias.
  • All-trans retinoic acid (ATRA) therapy for acute promyelocytic leukemia (APL) exemplifies successful NR-targeted differentiation therapy.

Purpose of the Study:

  • To review recent findings on the therapeutic potential of specific NRs in acute and chronic myeloid leukemia.
  • To focus on the roles of retinoic acid receptor (RAR), vitamin D receptor (VDR), peroxisome proliferator-activated receptor (PPAR), and retinoid X receptor (RXR).

Main Methods:

  • Literature review of recent research findings on NRs in myeloid leukemia.
  • Analysis of studies investigating the effects of NR agonists on leukemic cells.
  • Discussion of therapeutic strategies involving NR agonists, alone or in combination therapies.

Main Results:

  • NRs like RAR, VDR, and PPAR can inhibit proliferation, induce differentiation, and promote apoptosis in leukemic cells.
  • Combining different NR agonists or adding them to chemotherapy can yield synergistic anti-leukemic effects.
  • The success of ATRA in APL highlights the potential of NR-targeted differentiation therapy.

Conclusions:

  • Selected NRs (RAR, VDR, PPAR, RXR) hold significant therapeutic promise for myeloid leukemias.
  • Further mechanistic studies are needed to fully elucidate NR functions in leukemia.
  • Expanded research could lead to broader clinical applications of existing NR-targeting agents.
Keywords:
AMLATRACMLPPARRARRXRVDR

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.5K
Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

13.0K

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
2.2K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.6K
Signal Transduction: Overview01:26

Signal Transduction: Overview

Cells respond to many types of information, often through receptor proteins positioned on the membrane. They respond to chemical signals, such as hormones, neurotransmitters, and other signaling molecules, initiating a series of molecular reactions to produce an appropriate response. This is called signal transduction. Cells also coordinate different responses elicited by the same signaling molecule via mediators, allowing molecular cross-talk.
Typically, signal transduction involves three...
10.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K